Authors: Lacroix, Ludovic; Commo, Frdric; Soria, Jean-Charles

Source: Expert Review of Molecular Diagnostics, Volume 8, Number 2, March 2008 , pp. 167-178(12)

Publisher: Expert Reviews

Abstract:

Lung cancer is the leading cause of cancer worldwide. Despite recent advances in the management of resected lung cancer tumors (i.e., the use of adjuvant therapy) and more effective treatments in the metastatic setting (i.e., molecular targeted agents), the cure rate of lung cancer remains low. Successful molecular testing of lung cancer requires the identification and understanding of events that take place during the multistep tumorigenic process of lung cancer. As with other solid tumors, lung cancer is the result of the accumulation of genetic and epigenetic alterations over a long course of exposure to a carcinogen, such as tobacco smoke. Discovering new prognostic or predictive biomarkers or developing new detection tools for lung cancer is one of the major areas of translational cancer research. However, given our current understanding of the multifactorial process of lung carcinogenesis and the heterogeneous nature of the disease, monitoring of one or a few genes is limited. A pangenomic analysis seems more efficient for deciphering the complexity of lung cancer. The prospect of identifying specific events in lung carcinogenesis is significantly brightened by the recent development of high-throughput gene expression analysis. Since 2000, several studies have reported on the molecular classification of human lung carcinomas on the basis of gene expression and have described numerous putative biological markers of cancer. At this time, improving the biological significance of microarray data appears to be an important challenge. The most recent studies propose refining molecular classification of non-small-cell lung cancer on the basis of mRNA expression profiles. Other studies described new prognostic biomarkers that will be useful for the therapeutic management of patients bearing lung cancer (non-small-cell lung cancer). The present review summarizes the main recent advances associated with gene expression analysis in the field of lung cancer and, notably, non-small-cell lung tumors.

Keywords: DNA microarray; gene expression; lung cancer; microarray; molecular profiling; non-small-celllung cancer

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737159.8.2.167

Affiliations: 1: Institut de Cancrologie Gustave Roussy, Translational Research Laboratory, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France., Email: ludovic.lacroix@igr.fr

Publication date: 2008-03-01

More about this publication?

• Expert Review of Molecular Diagnostics provides expert reviews on molecular diagnostic technologies and applied pharmacogenomics in clinical medicine. Coverage includes molecular diagnostics, biomarkers, diagnostic technologies, microarrays and biochips, proteomics, pharmacogenomics, pharmacogenetics and personalized medicine.
• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• Information for Librarians
• Free Trials
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Biology ,  Genetics
• By this author: Lacroix, Ludovic ;  Commo, Frdric ;  Soria, Jean-Charles

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers